Cargando…

p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer

Adaptation of the lipid metabolism participates  in cancer pathogenesis, facilitating energy storage and influencing cell fate and control of molecular signalling. The tumour suppressor protein p53 is a molecular hub of cell metabolism, supporting antioxidant capabilities and counteracting oncogene-...

Descripción completa

Detalles Bibliográficos
Autores principales: Butera, Alessio, Roy, Micaela, Zampieri, Carlotta, Mammarella, Eleonora, Panatta, Emanuele, Melino, Gerry, D’Alessandro, Angelo, Amelio, Ivano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902766/
https://www.ncbi.nlm.nih.gov/pubmed/35255936
http://dx.doi.org/10.1186/s13062-022-00319-9
_version_ 1784664659262963712
author Butera, Alessio
Roy, Micaela
Zampieri, Carlotta
Mammarella, Eleonora
Panatta, Emanuele
Melino, Gerry
D’Alessandro, Angelo
Amelio, Ivano
author_facet Butera, Alessio
Roy, Micaela
Zampieri, Carlotta
Mammarella, Eleonora
Panatta, Emanuele
Melino, Gerry
D’Alessandro, Angelo
Amelio, Ivano
author_sort Butera, Alessio
collection PubMed
description Adaptation of the lipid metabolism participates  in cancer pathogenesis, facilitating energy storage and influencing cell fate and control of molecular signalling. The tumour suppressor protein p53 is a molecular hub of cell metabolism, supporting antioxidant capabilities and counteracting oncogene-induced metabolic switch. Despite extensive work has described the p53-dependent metabolic pathways, a global profiling of p53 lipidome is still missing. By high-throughput untargeted lipidomic analysis of pancreatic ductal adenocarcinoma (PDAC) cells, we profile the p53-dependent lipidome, revealing intracellular and secreted lysophospholipids as one of the most affected class. Lysophospholipids are hydrolysed forms of phospholipids that results from phospholipase activity, which can function as signalling molecules, exerting non-cell-autonomous effects and instructing cancer microenvironment and immunity. Here, we reveal that p53 depletion reduces abundance of intracellular lysophosphatidyl-choline, -ethanolamine and -serine and their secretion in the extracellular environment. By integrating this with genomic and transcriptomic studies from in vitro models and human PDAC patients, we identified potential clinically relevant candidate p53-dependent phospholipases. In particular PLD3, PLCB4 and PLCD4 expression is regulated by p53 and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) indicates a direct transcriptional control on their chromatin accessible genomic loci. Consistently, PLD3, PLCB4 and PLCD4 expression correlates with p53 mutational status in PDAC patients, and these genes display prognostic significance. Overall, our data provide insights into lipidome rewiring driven by p53 loss and identify alterations of lysophospholipids as a potential molecular mechanism for p53-mediated non-cell-autonomous molecular signalling that instructs cancer microenvironment and immunity during PDAC pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00319-9.
format Online
Article
Text
id pubmed-8902766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89027662022-03-18 p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer Butera, Alessio Roy, Micaela Zampieri, Carlotta Mammarella, Eleonora Panatta, Emanuele Melino, Gerry D’Alessandro, Angelo Amelio, Ivano Biol Direct Research Adaptation of the lipid metabolism participates  in cancer pathogenesis, facilitating energy storage and influencing cell fate and control of molecular signalling. The tumour suppressor protein p53 is a molecular hub of cell metabolism, supporting antioxidant capabilities and counteracting oncogene-induced metabolic switch. Despite extensive work has described the p53-dependent metabolic pathways, a global profiling of p53 lipidome is still missing. By high-throughput untargeted lipidomic analysis of pancreatic ductal adenocarcinoma (PDAC) cells, we profile the p53-dependent lipidome, revealing intracellular and secreted lysophospholipids as one of the most affected class. Lysophospholipids are hydrolysed forms of phospholipids that results from phospholipase activity, which can function as signalling molecules, exerting non-cell-autonomous effects and instructing cancer microenvironment and immunity. Here, we reveal that p53 depletion reduces abundance of intracellular lysophosphatidyl-choline, -ethanolamine and -serine and their secretion in the extracellular environment. By integrating this with genomic and transcriptomic studies from in vitro models and human PDAC patients, we identified potential clinically relevant candidate p53-dependent phospholipases. In particular PLD3, PLCB4 and PLCD4 expression is regulated by p53 and chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) indicates a direct transcriptional control on their chromatin accessible genomic loci. Consistently, PLD3, PLCB4 and PLCD4 expression correlates with p53 mutational status in PDAC patients, and these genes display prognostic significance. Overall, our data provide insights into lipidome rewiring driven by p53 loss and identify alterations of lysophospholipids as a potential molecular mechanism for p53-mediated non-cell-autonomous molecular signalling that instructs cancer microenvironment and immunity during PDAC pathogenesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00319-9. BioMed Central 2022-03-08 /pmc/articles/PMC8902766/ /pubmed/35255936 http://dx.doi.org/10.1186/s13062-022-00319-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Butera, Alessio
Roy, Micaela
Zampieri, Carlotta
Mammarella, Eleonora
Panatta, Emanuele
Melino, Gerry
D’Alessandro, Angelo
Amelio, Ivano
p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title_full p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title_fullStr p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title_full_unstemmed p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title_short p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
title_sort p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902766/
https://www.ncbi.nlm.nih.gov/pubmed/35255936
http://dx.doi.org/10.1186/s13062-022-00319-9
work_keys_str_mv AT buteraalessio p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT roymicaela p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT zampiericarlotta p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT mammarellaeleonora p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT panattaemanuele p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT melinogerry p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT dalessandroangelo p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer
AT amelioivano p53drivenlipidomeinfluencesnoncellautonomouslysophospholipidsinpancreaticcancer